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Abstract
Background: In the pathogenesis of limbic encephalitis other promoting factors besides the pure existence of
autoantibodies are increasingly discussed to play a significant role. This is to our knowledge the first described
patient in whom the presence of autoantibodies precedes the manifestation of limbic encephalitis for many years.
Case presentation: At the age of 38 years, in the serum of a patient with polyendocrine autoimmunity high titers
of cytoplasmic islet cell antibodies and of anti-glutamate decarboxylase (GAD) 65 antibodies were observed as an
incidential finding, GAD67 antibodies were negative at that time. After a latency of 18 years, she manifested with
refractory temporal lobe epilepsy most likely due to autoimmune limbic encephalitis. After epilepsy onset, the
patient underwent magnetic resonance imaging (MRI), electroencephalography, cerebrospinal fluid (CSF), serum
and neuropsychological investigations during a follow-up period of 8 years. A pharmacoresistent epilepsy with
seizure onset from the right temporal lobe and declarative memory deficits were observed affecting primarily the
recall of verbal informations. MRI showed a slightly increased signal in the right amygdala without progression.
GAD antibodies could be detected in serum (titre 1: 1000) and CSF (titre 1:1) by immunofluorescence. Both, GAD65
and GAD67 antibodies were observed in cell-based assays.
Conclusions: It can be assumed that in addition to a pre-existing systemic T-cell response associated with the
longstanding polyendocrine autoimmunity, a delayed intrathecal autoimmunity developed leading to limbic
encephalitis. This change might be reflected by the development of GAD67 antibodies in our patient. Besides the
contribution of this case report to a better understandig of the pathomechanisms for the development of central
nervous system (CNS) autoimmunity, it also has a clinical impact as early treatment of GAD antibody-associated
CNS disorders has a better prognosis. Therefore, vigilance for symptoms indicating GAD antibody-associated CNS
autoimmunity is mandatory in patients with GAD antibody-associated endocrine dysfunction.
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Background
Limbic encephalitis describes a heterogenous spectrum of
neurological disorders characterized by mostly subacute
onset and progressive mnestic deficits, epileptic seizures
and psychiatric disturbances such as depression and
psychosis. A variety of autoantibodies against brain anti-
gens has been detected in association with limbic enceph-
alitis. These include onconeuronal antibodies against
intracellular proteins (Hu, Ma2, CV2) in the context with
malignant tumors [1] and a multitude of other distinct
pathogenic autoantibodies against surface protein recep-
tors in the absence or presence of tumors [2] .
Anti-glutamic acid decarboxylase (GAD) antibodies oc-
cupy an intermediate position, as they are directed against
an intracellular antigen but are not associated with malig-
nant tumors in the majority of cases [2]. Two distinct GAD
isoforms exist in humans, GAD65 and GAD67, which are
encoded by different genes and share approximately
75 % amino acid sequence identity [3]. Both isoforms
are expressed in islet cells and GABAergic neurons, al-
though GAD65 at higher levels. The molecular nature
of GAD antibodies is partly distinct in different clinical
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conditions [4]. Patients with GAD antibodies manifest
with different clinical disorders, either with or without
neurological dysfunction. Non-neurological disorders
comprise type 1 diabetes mellitus alone or polyendo-
crine autoimmunity with or without diabetes [5, 6]
while neurological disorders associated with GAD anti-
bodies include stiff person syndrome (SPS), cerebellar
ataxia and limbic encephalitis sometimes presenting as
therapy refractory temporal lobe epilepsy [7, 8]. While
GAD antibodies in autoimmune endocrinopathies
recognize conformational epitopes on GAD65 and the
infrequent recognition of GAD67 isoform is assumed
as cross-reactivity phenomenon [9], the antibodies in
SPS and cerebellar ataxia recognize linear epitopes on
GAD65 so they can be detected by Western blotting
and frequently recognize GAD67 [10, 11, 12, 13].
Whereas a direct pathogenic mechanism of autoanti-
bodies was demonstrated for antibodies to the N-
methyl-D-aspartate receptor (NMDAR antibodies) [14]
and can be assumed for limbic encephalitis associated
with others surface protein autoantibodies [2], in cases
with antibodies against intracellular antigens including
GAD antibodies, the toxic effect on the central nervous
system (CNS) is more probably mediated by cytotoxic
T cells [2]. However, even in autoimmune encephalitis
associated with NMDAR antibodies, it has been re-
cently shown that an intrathecal antibody synthesis can
persist for a long time after remission of acute NMDAR
encephalitis [15]. Thus, other promoting factors seem
to be essential to establish the clinical phenotype. Blood
brain barrier function and antibody affinity have been
discussed as such further important promoting factors.
Here, we report the first patient with limbic encephal-
itis associated with antibodies to GAD in whom these
antibodies had already been detected 18 years before the
patient became symptomatic with epileptic seizures and
mnestic deficits. This case report adds to the medical lit-
erature that in longstanding polyendocrine autoimmun-
ity a delayed intrathecal spread is possible leading many
years later to limbic encephalitis.
Case presentation
At the age of 38 years, the female patient participated as
a healthy control in scientific studies concerning cyto-
plasmic islet cell antibodies (ICA) in insulin-dependent
diabetes using an indirect immunofluorescence tests on
cryostat sections of human pancreas [16–18]. At that time
she neither suffered from diabetes mellitus nor presented
with any neurological symptoms. However, at the same
time, she was diagnosed for autoimmune thyroiditis
with high-titre antibodies to thyroid microsomal antigens
(although hypothyreoidism had already been known for
several years and treated with L-thyroxin), she had vitiligo
and antibodies to gastric parietal cells as well as antibodies
to the intrinsic factor. At that time - as an incidential
finding - high titers of ICA (reportedly >1:128, immu-
nefluorescence on human pancreas) and GAD anti-
bodies were observed in the patient’s serum. The GAD
antibodies were directed to the GAD65 antigen only.
Antibodies to GAD67 were negative at that time [5].
The ICA reactivity could not be eliminated by preincuba-
tion with GAD65 indicating additional antigens against
which the ICA was directed [17].
At the age of 56 years, the patient presented with first
epileptic seizures. Seizure semiology consisted mainly in
simple partial seizures with tightness in the chest accom-
panied by anxiety resembling angina pectoris. These sei-
zures lasted for 0.5 to 3 min. During most of these
seizures, she was adequately responsive to verbal and non-
verbal commands. Sometimes, there was a transition to
complex partial seizures of temporal semiology. Report-
edly, she was unresponsive and appeared helpless. More-
over, she showed fumbling manual automatisms for about
2 to 3 min. The patient had amnesia for these episodes.
Additionally she reported acoustic hallucinations in
terms of a perception of music/melodies. Generalised
tonic-clonic seizures never occurred. Seizure frequency
was several simple partial and complex partial seizures
per month. Simultaneously with epilepsy onset, the pa-
tient complained of considerable memory impairment.
A first neuropsychological examination revealed signifi-
cant episodic memory deficits that affected primarily
the recall of verbal information. The figural episodic
memory as well as primary verbal memory and verbal flu-
ency were only slightly reduced. Information processing
speed, divided and selective attention were in the normal
range. Initial cerebrospinal fluid (CSF) examination at the
age of 56 was normal (0 leucocyte, total protein 324 mg/l,
lactate 1,6 mmol/l, oligoclonal and oligoclonal IgG n
serum and CSF negative).
In the cerebral magnetic resonance imaging (MRI) per-
formed three years later, a slight T2-hyperintensity of the
right amygdala without increased volume was observed.
At the age of 60, video-electroencephalography (EEG)
monitoring was performed. Interictal epileptiform dis-
charges were seen in the right temporo-anterior region.
One habitual complex partial seizure could be registered
with EEG onset also over the right temporal lobe. In a
neuropsychological follow-up performed, a substantial
worsening of the figural episodic memory performance
was found, whereas episodic verbal memory and verbal
fluency presented nearly normal. Repeated CSF ana-
lysis at the age of 60 again revealed a normal cell count
(1 cells/μl), CSF/blood barrier function (total protein
271 mg/l, CSF/serum albumin ratio 3.0 x 10−3) and ab-
sent intrathecal immunoglobulin synthesis. However,
GAD antibodies were highly positive in both serum and
CSF when tested by a GAD65 ELISA (serum 15.800 U/ml,
Fauser et al. BMC Neurology  (2015) 15:177 Page 2 of 5
CSF 48 U/ml) as described [7] or using immunofluores-
cence on primate cerebellum (serum 1:1000, CSF 1:1)
(Fig. 1a-c) and rat brain (serum 1:64,000, CSF 1:8) [7]. GAD
antibodies in serum recognized a linear GAD65 epitope, as
suggested by the positive reactivity in immunoblots using
recombinant GAD65 protein [13]. Concomitant antibodies
against GAD67 (serum 1:40, CSF 1:5) were found in serum
and CSF using a cell-based assay [19]. Indirect immuno-
fluorescence using both rat brain and primate cerebellum,
pancreas and gut did not reveal the presence of antibodies
at relevant titres to neuronal antigens other than GAD.
Specific subtests could exclude NMDAR, CASPR2, LGI1,
AMPAR, GABABR and GABAAR antibodies in serum and
CSF and GlyR, Aquaporin 4, Hu, Yo, Ri, CV2, Tr, Ma1/2,
Zic4 antibodies in serum.
In the following years, the epilepsy took a pharmacore-
sistent course. The patient was treated by levetiracetam,
lamotrigine and zonisamide without relevant improve-
ment. The MRI abnormality remained unchanged over an
observation time of 3 years (Fig. 1d). A further neuro-
psychological assessment at the age of 62 revealed again
mnestic deficits mainly concerning the recall of verbal epi-
sodic information and – to a less severe degree - the pri-
mary verbal memory while non-verbal memory functions
had improved. Moreover, the patient presented with defi-
cits in the selective attention and with emotional lability
as well as moderate depressive symptomes. However, dur-
ing the course of the disease the patient remained able to
work. At the age of 63, the patient received two cycle of
high-dose methylprednisolone (1 g /daily for 5 consecutive
days every four months). In parallel, the seizure frequency
decreased considerably to less than once per month al-
though in parallel her antiepileptic therapy was comple-
mented by perampanel.
Until present, the patient has not developed diabetes
mellitus.
Based on the clinical findings of late-onset temporal
lobe epilepsy with a pharmacoresistant course, impair-
ment of both, verbal and nonverbal declarative memory,
a slight increase of signal intensity in the right amyg-
dala without hippocampal atrophy or sclerosis and high
GAD65 and positive GAD67 antibodies in serum and
CSF, a GAD antibody-associated limbic encephalitis
was diagnosed.
Conclusion
Initially, GAD antibodies in our patient were only associ-
ated with endocrine autoimmunity for many years. Thus,
our case illustrates that besides the pure presence of the
autoantibodies other promoting factors must play a role in
the pathogenesis of limbic encephalitis. Whereas complete
recovery from symptoms of autoimmune encephalitis has
Fig. 1 Immunofluorescence findings and magnetic resonance imaging in our case of GAD antibody-associated limbic encephalitis. a-c Micrographs
showing immunofluorescence using the patient’s serum diluted 1:100 (a/c) or CSF diluted 1:1 (b) on primate cerebellum (a/b) or pancreas (c)
(bar = 100 μm). Note the typical fluorescence pattern for GAD antibodies with prominent fluorescence in the granule cell layer and a subset of
islet cells and less prominent signal in Purkinje cells. d T2-weighted magnetic resonance imaging demonstrates a slight signal hyperintensity
of the right amygdala/anterior hippocampus compatible with the diagnosis of limbic encephalitis
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been described despite the persistence of autoantibodies
[15], our patient is to our knowledge the first in whom the
presence of autoantibodies preceded the manifestation of
limbic encephalitis for many years. Although autoimmune
encephalitis in terms of GAD autoimmunity cannot be
proven in our patient, there are many arguments in favor
of this hypothesis. First, high antibody levels were found
in the range previously described associated with GAD
antibody-associated neurological syndromes [7], which de-
tected a linear epitope as found in other GAD antibody-
associated CNS disorders [13]. Second, GAD67 antibodies
were positive in the CSF, a finding invariably present in
patients with GAD antibody-associated disorders of the
CNS [19]. Third, the clinical course with prominent phar-
macoresistant epilepsy and less apparent psychiatric and
cognitive disturbances is typical of GAD antibody-positive
limbic encephalitis [8]. Fourth, in cranial MRI a slight in-
crease of signal intensity was seen in the right amygdala
without enlarged volume or hippocampal sclerosis, which
remained without progression over three years. Thus, a
low-grade brain tumor, mesial temporal sclerosis or a dys-
plasia is unlikely to exist in this case.
How could the long latency between the appearance of
GAD antibodies and the clinical manifestation of limbic
encephalitis be explained? In NMDAR encephalitis, in con-
trast to GAD antibody-associated syndromes, the NMDAR
antibodies play a pathophysiologically relevant role [14].
Here, a spread from systemic to intrathecal autoimmunity
against NMDARs is hypothesized to trigger the onset of
the encephalitis [20]. In patients with antibodies against
intracellular antigens, including those with GAD anti-
bodies, a higher CD8/CD3 ratio and more frequent apposi-
tions of granzyme-B(+) cytotoxic T cells to neurons were
found compared to the patients with surface antigens [21].
In analogy with NMDAR encephalitis, however, it can be
assumed that in addition to the pre-existing systemic T cell
response associated with the longstanding polyendocrine
autoimmunity in our patient, a delayed intrathecal auto-
immunity developed leading to limbic encephalitis. This
change might be reflected by the development of GAD67
antibodies in our patient. Moreover, a (transient) blood–
brain barrier disruption might have played an important
part in the reported patient. Alternatively, the epilepsy may
not have occurred immediately after tissue damage but
after a longer latency period in which remodelling of
synapses finally lead to epileptogenesis similar to hippo-
campal sclerosis.
In conclusion, our case shows that systemic GAD
autoimmunity, even after many years, can spread to the
CNS. Moreover, our case underlines that the presence
of one or more autoimmune disorders is an indicator
that epilepsy may be of autoimmune origin [22]. As
early treatment of GAD antibody-associated CNS disor-
ders has a better prognosis [19], vigilance for symptoms
indicating GAD antibody-associated CNS autoimmunity
is mandatory in patients with GAD antibody-associated
endocrine dysfunction.
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